Price
85.93
-0.85%52W Range
Market Cap
₹136.81 Cr
Traded: ₹0.08 Cr (0.06%) 0.0x
Free Float: ₹48.22 Cr (0.16% of FF traded)
Volume · 60D trend
8.96 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | +16.0% | +6.0% | +35.0% | -- | -13.0% | Stable |
| Return | +1.0% | -2.0% | +5.0% | -3.0% | -- | Stable |
| ROE | +5.0% | +8.0% | +9.0% | -- | -- | Accelerating |
| Sales | +5.0% | +4.0% | +1.0% | -- | +3.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 89 | 84 | 88 | 74 | 66 | 82 | 73 | 74 | 74 | 95 | 82 | 93 | 70 | 82 | 77 | 75 |
| Expenses | 81 | 74 | 78 | 68 | 60 | 74 | 65 | 66 | 68 | 85 | 74 | 85 | 64 | 74 | 70 | 70 |
| Operating Profit | 8 | 11 | 10 | 6 | 6 | 8 | 8 | 8 | 6 | 10 | 8 | 8 | 6 | 8 | 6 | 6 |
| OPM % | 9.0% | 12.6% | 10.9% | 7.7% | 9.2% | 9.3% | 10.6% | 10.4% | 8.7% | 10.1% | 9.5% | 8.3% | 9.2% | 9.9% | 8.0% | 7.7% |
| Other Income | 0 | -0 | 0 | 1 | 1 | 1 | 1 | -0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Depreciation | 3 | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 2 |
| Profit Before Tax | 1 | 3 | 2 | 1 | 0 | 3 | 1 | 1 | 1 | 6 | 1 | 2 | 0 | 2 | 1 | 1 |
| Tax % | 0.0% | -12.1% | 0.0% | 0.0% | 0.0% | -108.9% | 7.1% | 23.5% | 58.1% | 3.6% | 33.1% | 39.4% | 79.1% | 32.8% | 43.8% | 78.3% |
| Net Profit | 1 | 4 | 2 | 1 | 0 | 5 | 1 | 1 | 0 | 6 | 1 | 1 | 0 | 2 | 1 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.7 | 2.3 | 1.1 | 0.5 | 0.1 | 3.4 | 0.3 | 0.7 | 0.2 | 3.5 | 0.6 | 0.6 | 0.1 | 1.0 | 0.4 | 0.1 |
| Sales Growth (YoY) | -- | 2.7% | 19.9% | 0.5% | -11.4% | -13.5% | -10.4% | -20.4% | 5.6% | 14.8% | 6.6% | 22.9% | 0.8% | 11.3% | -- | -- |
| Sales Growth (QoQ) | -- | -4.1% | 18.5% | 12.4% | -19.6% | 11.9% | -0.7% | -0.9% | -21.4% | 15.9% | -11.8% | 31.5% | -14.6% | 7.6% | 1.7% | -- |
| OP Growth (YoY) | 31.2% | 38.5% | 23.1% | -25.5% | -6.3% | -20.4% | -0.5% | -0.1% | 0.5% | 17.6% | 26.7% | 33.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | -24.9% | 10.9% | 66.5% | -5.4% | -20.7% | -1.4% | 0.8% | 18.9% | -32.6% | 23.2% | 1.2% | 19.6% | -21.1% | 32.7% | 6.4% | -- |
| Profit Growth (YoY) | -- | -33.9% | 270.8% | -31.7% | -23.1% | -0.7% | -46.1% | 9.5% | 225.0% | 241.9% | 56.1% | 763.6% | -71.4% | -18.8% | -11.0% | -92.0% |
| EPS Growth (YoY) | -- | -34.0% | 273.3% | -30.8% | -18.8% | -1.4% | -46.4% | 6.6% | 220.0% | 239.2% | 55.6% | 771.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 100.9% | 148.9% | 246.2% | -96.2% | 1036.7% | -53.9% | 306.3% | -95.4% | 517.9% | -8.2% | 1120.0% | -95.1% | 183.3% | 414.3% | -- |
| OP Margin | -- | 12.6% | 10.9% | 7.7% | 9.2% | 9.3% | 10.6% | 10.4% | 8.7% | 10.1% | 9.5% | 8.3% | 9.2% | 9.9% | 8.0% | 7.7% |
| Net Margin | -- | 4.3% | 2.0% | 1.0% | 0.3% | 6.6% | 0.7% | 1.4% | 0.3% | 5.8% | 1.0% | 1.1% | 0.1% | 2.0% | 0.8% | 0.2% |
| Material Cost % | 58.0% | 46.0% | 53.0% | 54.0% | 51.0% | 54.0% | 50.0% | 52.0% | 53.0% | 57.0% | 56.0% | 58.0% | 55.0% | 54.7% | 59.0% | 56.0% |
| Employee Cost % | 19.0% | 21.0% | 20.0% | 22.0% | 22.0% | 19.0% | 22.0% | 22.0% | 20.0% | 17.0% | 19.0% | 17.0% | 20.0% | 17.7% | 18.0% | 19.0% |
| P/S | 0.41 | 0.46 | 0.50 | 0.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 19.01 | 22.91 | 18.87 | 17.55 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.67 | 1.76 | 1.97 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50In Continuation of Outcome of Board meeting dated August 12 2026 , Published Unaudited Financial result for the quarter ended 30th June 2026 and IEPF Notice in Financial express and Sanjevani ....
Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone ....
Enclosed Financial Result for the First quarter ended 30th June 2026 together with Limited Review Report as submitted by Statutory auditor
Outcome : Result of Postal Ballot Notice dated July 09 2026 read with its Corrigendum dated July 23 , 2026
Scrutinizers Report Pertaining to Postal Ballot Notice dated July 09 2026 read with its Corrigendum dated July 23rd 2026.
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 and other ....
In Continuation of Postal Ballot Notice dated 09th July 2026 , Submitting Corrigendum as integral part to the Said Notice.
Certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended 30.06.2026
Postal Ballot Notice for consider the issue of 1000000 Warrants to Mr. Shailesh Siroya , promoter of the Company on preferential basis
Trading window closure for the quarter ended 30.06.2026.
This is with reference to our earlier intimation dated 27th May 2026 regarding appointment of Mr. Shreepada ML as company secretary and compliance officer of the company pursuant to the ....
Filing of Statement of deviation & variation is not applicable to the Company for the quarter ended 31.03.2026.
We are submitting the newspaper advertisements of the Audited financial results ( standalone & Consolidated ) for the quarter and financial year ended 31.03.2026 announced by the Company ....
Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend ....
Audited financial results of the company for the quarter and financial year ended 31.03.2026.
Annual Secretarial Compliance Report for the financial year ended 31.03.2026.
In addition to the agenda items mentioned in our board meeting notice dated 18.05.2025, the following agenda item will also be considered at the meeting scheduled on 27.05.2026. 1. To ....
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve 1. Audited financial results of ....
Intimation on resignation of Company Secretary & Compliance officer.
Certificate under Regulation 74(5) of SEBI(DP) Regulations, for the quarter ended 31.03.2026.
Closure of Trading Window for the quarter and financial year ended 31.03.2026.
Newspaper publication of Unaudited financial results for the quarter ended 31.12.2025.
Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.
Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.
Dr.Mukesh Beekamchand ( DIN # 11295580 ) is appointed as Non executive Independent Director of the Company through an ordinary resolution passed by the members of the Company through postal ....
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve Unaudited standalone and consolidated ....
We are submitting newspaper advertisements of the postal ballot notice issued by the Company on 08.01.2026 and published on 09.01.2026.
Confirmation as per Regulation 74(5) of SEBI(DP) Regulations, for the quarter ended 31.12.2025.
Postal Ballot notice for appointment of Dr.Mukesh Beekamchand ( DIN # 11295580) as independent Director of the Company.
Trading Window Closure from 1st January 2026 to 16th February 2026- for announcing unaudited financial results for the quarter ended 31.12.2025.
We are submitting to the exchanges, news paper advertisements of the unaudited standalone and consolidated financial results of the company for the quarter ended 30.09.2029 announced by ....
Unaudited standalone and Consolidated financial results for the quarter ended 30.09.2025.
Board of Directors of the Company has inter alia 1. Approved the unaudited standalone and consolidate financial results for the quarter ended 30.09.2025. 2. Appointed Dr.B.Mukesh ( DIN ....
Clarification on the outcome of the board meeting held on 11.08.2025.
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve standalone and consolidated financial ....
Confirmation as per Regulation 74(5) of SEBI(DP) Regulations for the quarter ended 30.09.2025.
Completion of term of Mr.H.S Venkatesh ( DIN # 01776040) as Independent Director of the Company.
Trading Window on dealing with the securities of the Company will be closed from 1st October 2025 until 48 hours of announcement of Unaudited financial results of the Company for the qtr ....
Outcome of the 38th Annual General Meeting of the Company.
Newpaper Publication for Notice for the 38th Annual General Meeting of the Company together with e-voting and Book closure .
We are submitting the Copy of the unabridged Annual Report, for the financial year ended 31.03.2025.
Newpaper Publication of the Unaudited financial results for the quarter ended 30.06.2025.
The Board of Directors at their meeting held on 11.08.2025 has fixed 18th September 2025 as record date for the payment of dividend for the financial year ended 31.03.2025, which is subject ....
Unaudited financial results ( Standalone and consolidated ) for the quarter ended 30.06.2025.
Board of Directors of the Company has met today and inter alia transacted the following business, 1. Approved the unaudited financial results ( standalone and consolidated ) for the quarter ....
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 ,inter alia, to consider and approve 1. Unaudited financial results for ....
We are submitting to the exchanges newspaper advertisements of the notice issued to the shareholders regarding transfer of their shares to IEPF account , whose dividend is outstanding to ....
Certificate under Regulation 74(5) of SEBI(DP) Regulations, for the quarter ended 30.06.2025.
Newpaper publication of the Postal Ballot notice dated 30.06.2025.
Postal Ballot Notice
Annual Reports
15Credit Ratings
6